A 41-year-old woman presented with pyoderma gangrenosum involving the right eyelids. Over the course of 3 years, she developed progressive scarring of the eyelids with lagophthalmos and corneal exposure. Multiple reconstructive procedures were performed with varying degrees of success. Despite aggressive medical control of her disease, it recurred in grafted skin on her upper and lower eyelids as confirmed by tissue biopsy. Periocular pyoderma gangrenosum is a rare disease where the management may be complicated by disease recurrence in reconstructed tissues, including skin grafts as this case demonstrates.
To describe the visual field defects in retinoblastoma survivors and relate those defects to characteristics such as tumor size, tumor location, and treatment modality.Methods: Thirty-one patients treated for retinoblastoma were included in this study. Humphrey visual fields were determined in 33 eyes.Results: Twenty-seven patients (29 eyes, 68 tumors) had sufficient diagnosis and treatment data available for further analysis. Twenty-six of the 27 patients had both absolute and relative visual field defects. Four types of vi-sual field defects were observed and correlated with location of the tumor and therapy to the individual tumors: (1) no residual defect, (2) absolute scotoma, (3) arcuate and sector scotoma, and (4) "pseudo"-visual field defects caused by relative enophthalmos resulting from radiation.Conclusions: Patients with retinoblastoma demonstrate a variety of long-term visual field defects after treatment for their intraocular disease. Characteristics that determine the size and type of defects are tumor size, tumor location, and treatment method.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.